These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 33202419)

  • 61. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

  • 62. SARS-CoV-2 serology and virology trends in donors and recipients of convalescent plasma.
    Dulipsingh L; Ibrahim D; Schaefer EJ; Crowell R; Diffenderfer MR; Williams K; Lima C; McKenzie J; Cook L; Puff J; Onoroski M; Wakefield DB; Eadie RJ; Kleiboeker SB; Nabors P; Hussain SA
    Transfus Apher Sci; 2020 Dec; 59(6):102922. PubMed ID: 32883593
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
    Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
    Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Determination of neutralising anti-SARS-CoV-2 antibody half-life in COVID-19 convalescent donors.
    Barnes TW; Schulte-Pelkum J; Steller L; Filchtinski D; Jenness R; Williams MR; Kober C; Manni S; Hauser T; Hahn A; Kalina U; Simon TL; Schuetz P; Roth NJ
    Clin Immunol; 2021 Nov; 232():108871. PubMed ID: 34619377
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China.
    Ye M; Fu D; Ren Y; Wang F; Wang D; Zhang F; Xia X; Lv T
    J Med Virol; 2020 Oct; 92(10):1890-1901. PubMed ID: 32293713
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology.
    Yonemura S; Hartson L; Dutt TS; Henao-Tamayo M; Goodrich R; Marschner S
    Vox Sang; 2021 Nov; 116(10):1076-1083. PubMed ID: 33835489
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
    Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
    Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Clinical characteristics and plasma antibody titer of patients with COVID-19 in Zhejiang, China.
    Xiang WL; Cheng JJ; Wu LP; Chen BY; Li WX; Qiu DY; Zhang W; Ge FH; Chen D; Wang Z
    J Zhejiang Univ Sci B; 2020 Dec.; 21(12):955-960. PubMed ID: 33843161
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

  • 70. The Pre-Vaccination Donated Blood Is Free from Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) but Is Rich with Anti-SARS-CoV-2 Antibodies: A Cross-Section Saudi Study.
    Almaeen AH; Alduraywish AA; Ghazy AA; El-Metwally TH; Alayyaf M; Alrayes FH; Alinad AKM; Albulayhid SBH; Aldakhil AR; Taha AE
    Int J Environ Res Public Health; 2022 Jun; 19(12):. PubMed ID: 35742368
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term antibody titers variation in unvaccinated patients receiving convalescent plasma or placebo for severe SARS-CoV-2 pulmonary infection.
    Scibona P; Burgos Pratx LD; Savoy N; Recart D; Elia Y; Seoane FN; Arrigo D; Portalis MR; Roldan A; Cassoratti BA; Diaz JC; Antonelli CE; Perez L; Posadas-Martinez L; Belloso WH; Simonovich V
    Transfus Apher Sci; 2023 Dec; 62(6):103785. PubMed ID: 37620184
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2.
    Burnouf T; Gathof B; Bloch EM; Bazin R; de Angelis V; Patidar GK; Rastvorceva RMG; Oreh A; Goel R; Rahimi-Levene N; Hindawi S; Al-Riyami AZ; So-Osman C;
    Transfus Med Rev; 2022 Jul; 36(3):125-132. PubMed ID: 35879213
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Stability and neutralising capacity of SARS-CoV-2-specific antibodies in convalescent plasma.
    Tonn T; Corman VM; Johnsen M; Richter A; Rodionov RN; Drosten C; Bornstein SR
    Lancet Microbe; 2020 Jun; 1(2):e63. PubMed ID: 32835332
    [No Abstract]   [Full Text] [Related]  

  • 74. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
    Raturi M; Kusum A; Kala M; Mittal G; Sharma A; Bansal N
    Transfus Clin Biol; 2021 Aug; 28(3):300-302. PubMed ID: 33971318
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019.
    Bloch EM; Focosi D; Shoham S; Senefeld J; Tobian AAR; Baden LR; Tiberghien P; Sullivan DJ; Cohn C; Dioverti V; Henderson JP; So-Osman C; Juskewitch JE; Razonable RR; Franchini M; Goel R; Grossman BJ; Casadevall A; Joyner MJ; Avery RK; Pirofski LA; Gebo KA
    Clin Infect Dis; 2023 Jun; 76(11):2018-2024. PubMed ID: 36740590
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.
    Khaire NS; Jindal N; Yaddanapudi LN; Sachdev S; Hans R; Sachdeva N; Singh MP; Agarwal A; Mukherjee A; Kumar G; Sharma RR; Suri V; Puri GD; Malhotra P
    Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):64-85. PubMed ID: 33818467
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
    Sheervalilou R; Shirvaliloo M; Sargazi S; Bahari S; Saravani R; Shahraki J; Shirvalilou S; Shahraki O; Nazarlou Z; Shams Z; Ghaznavi H
    Blood Purif; 2022; 51(1):1-14. PubMed ID: 33789273
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Management of COVID patients with convalescent plasma: Do we have the final word?
    Menichetti F; Falcone M; Tiseo G
    Eur J Intern Med; 2022 Jan; 95():13-16. PubMed ID: 34895816
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Serum anti-Spike immunoglobulin G levels in random blood donors in Italy: High-titre convalescent plasma is easier than ever to procure.
    Focosi D; Meschi S; Coen S; Iorio MC; Franchini M; Lanza M; Maggi F
    Vox Sang; 2023 Sep; 118(9):794-797. PubMed ID: 37489640
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Safety and efficacy of convalescent plasma therapy in severely and critically ill patients with COVID-19: a systematic review with meta-analysis.
    Wenjing L; Yuanzheng F; Li JY; Tang LV; Yu H
    Aging (Albany NY); 2020 Dec; 13(1):1498-1509. PubMed ID: 33323550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.